Table 2.
In-house and Referred Specimens Submitted for Lung Cancer, Colorectal Cancer, and Melanoma Panels
| In-house Specimen | Referred Specimens | ||||
|---|---|---|---|---|---|
| Total | Failed | Total | Failed | P Value | |
| Lung cancer panel | |||||
| Resection | 192 | 0 | 40 | 0 | |
| Biopsy | 131 | 5 (3.8%) | 91 | 9 (9.9%) | |
| FNA | 110 | 3 (2.7%) | 11 | 1 (9.1%) | |
| Effusion | 22 | 0 | 4 | 0 | |
| Other | 3 | 1 (33%) | 0 | ||
| Total NGS assay | 458 | 9 (2.0%) | 146 | 10 (6.9%) | <.01 |
| Total specimensa | 465 | 16 (3.4%) | 160 | 24 (15%) | <.001 |
| Colorectal cancer panel | |||||
| Resection | 205 | 2 (1.0%) | 52 | 1 (1.9%) | |
| Biopsy | 26 | 0 | 23 | 0 | |
| FNA | 4 | 0 | 0 | ||
| Effusion | 0 | 0 | |||
| Other | 1 | 0 | 0 | ||
| Total NGS assay | 236 | 2 (0.8%) | 75 | 1 (1.3%) | .56 |
| Total specimensa | 238 | 4 (1.7%) | 76 | 2 (2.6%) | .63 |
| Melanoma panel | |||||
| Resection | 55 | 1 (1.8%) | 32 | 0 | |
| Biopsy | 36 | 2 (5.6%) | 35 | 3 (8.6%) | |
| FNA | 5 | 0 | 0 | ||
| Effusion | 0 | 0 | |||
| Other | 0 | 0 | |||
| Total NGS assay | 96 | 3 (3.1%) | 67 | 3 (4.5%) | .69 |
| Total specimensa | 96 | 3 (3.1%) | 69 | 5 (7.2%) | .28 |
| Total NGS assay | 790 | 14 (1.8%) | 288 | 14 (4.9%) | <.01 |
| Total specimensa | 799 | 23 (2.9%) | 305 | 31 (10%) | <.001 |
FNA, fine needle aspiration; NGS, next-generation sequencing.
aTwenty-six specimens cancelled due to insufficient tumor tissues were included here as failed specimens to assess overall assay feasibility.